Current status of the taxanes as adjuvant therapy for breast cancer Journal Article
| Authors: | Hudis, C.; Mcarthur, H.; Dang, C. |
| Article Title: | Current status of the taxanes as adjuvant therapy for breast cancer |
| Abstract: | Adjuvant chemotherapy for breast cancer reduces the risks of recurrence and death in many subsets of patients. The quest for better regimens, defined as both more effective and less toxic has led to numerous clinical trials testing the taxanes in the adjuvant setting. These trials are generally positive but do not clearly identify a single best or ideal regimen for all patients. This paper reviews the available data in this area of clinical research. © 2007 Elsevier Ltd. All rights reserved. |
| Keywords: | treatment outcome; overall survival; clinical trial; neutropenia; doxorubicin; fluorouracil; drug efficacy; monotherapy; antineoplastic agents; paclitaxel; adjuvant therapy; disease free survival; chemotherapy, adjuvant; recurrence risk; multiple cycle treatment; neoplasm recurrence, local; breast cancer; stomatitis; epidermal growth factor receptor 2; combination chemotherapy; cyclophosphamide; breast neoplasms; cancer mortality; docetaxel; asthenia; drug hypersensitivity; febrile neutropenia; dosage schedule comparison; medical research; tamoxifen; cancer relapse; epirubicin; taxoids; taxane derivative; estrogen receptor; progesterone receptor; risk reduction; granulocyte colony stimulating factor; taxanes |
| Journal Title: | Breast |
| Volume: | 16 |
| Issue: | Suppl. 2 |
| ISSN: | 0960-9776 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2007-12-01 |
| Start Page: | 132 |
| End Page: | 135 |
| Language: | English |
| DOI: | 10.1016/j.breast.2007.07.022 |
| PUBMED: | 17723302 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 3" - "Export Date: 17 November 2011" - "CODEN: BREAE" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work